Sunesis is a clinical-stage biopharmaceutical company focused on the development and commercialization of novel small molecule therapeutics for oncology. Our experienced cancer drug development organization is committed to advancing vosaroxin through clinical trials. Sunesis' lead compound, vosaroxin, is currently being evaluated as a single agent in a Phase 2 clinical trial in platinum-resistant ovarian cancer, in a Phase 2 clinical trial (known as the REVEAL-1 trial) in previously untreated... More >> |  | |
|
| Date | Title | | | | 12/12/11 | Sunesis Announces Participation in Cardiff University Sponsored Phase 2/3 Trial Evaluating Vosaroxin in Newly Diagnosed Elderly AML and High-Risk MDS Patients| SOUTH SAN FRANCISCO, Calif., Dec. 12, 2011 (GLOBE NEWSWIRE) -- Sunesis Pharmaceuticals, Inc. (Nasdaq:SNSS) today announced participation in a Phase 2/3 randomized, controlled, multicenter trial evaluating novel treatment regimens against low dose cytarabine (LD Ara-C), a commonly used treatment of elderly patients with acute myeloid leukemia (AML) and high-risk myelodysplastic syndrome (MDS). This trial, known as the Less Intensive 1 (LI-1) Study, is being conducted by the United Kingdom's Natio... |
|  |  | | 12/09/11 | Data and Safety Monitoring Board Recommends Continuation of Sunesis Pharmaceuticals' VALOR Trial Based on Periodic Safety Review| Company Remains on Track for Interim Analysis in Mid-2012
SOUTH SAN FRANCISCO, Calif., Dec 9, 2011 (GlobeNewswire via COMTEX) -- Sunesis Pharmaceuticals, Inc. (Nasdaq:SNSS) today announced that the independent Data and Safety Monitoring Board (DSMB) for the VALOR trial has completed a planned periodic safety review and recommended that the trial continue as planned without changes to study conduct. The VALOR trial is a Phase 3, randomized, double-blind, placebo-controlled, pivotal trial of vos... |
| | | | 12/06/11 | Sunesis to Present at the Oppenheimer 22nd Annual Healthcare Conference| SOUTH SAN FRANCISCO, Calif., Dec 6, 2011 (GlobeNewswire via COMTEX) --Sunesis Pharmaceuticals, Inc. (Nasdaq:SNSS) today announced that Daniel Swisher, Chief Executive Officer of Sunesis, will be presenting at the Oppenheimer 22nd Annual Healthcare Conference on Tuesday, December 13, 2011 at 9:40 AM Eastern Time at the Waldorf=Astoria in New York City.
A live webcast of the presentation will be available on the Sunesis website at http://ir.sunesis.com. A replay of the webcast will be archive... |
| | |
|
|
| There are currently no events scheduled. |
Receive E-mail Alerts |
| Sign up to receive e-mail alerts whenever Sunesis Pharmaceuticals, Inc. posts new information to the site. Just enter your e-mail address and click Submit. |
Replication or redistribution of EDGAR Online, Inc. content is expressly prohibited without the prior written consent of EDGAR Online, Inc. EDGAR Online, Inc. shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon. |
Sunesis is a biopharmaceutical company focused on new oncology therapeutics for the treatment of solid and hematologic cancers.
Listen to recent webcasts of presentation conference calls, earnings calls, and more.
Copyright © Sunesis Pharmaceuticals, Inc. 2010. All Rights Reserved.
